Teicoplanin Allergy Testing Using Autologous Serum (TATAS)

NCT ID: NCT06803758

Last Updated: 2025-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-08

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Allergy testing for Teicoplanin is much more unreliable than for other similar drugs. This means that we run the risk of missing serious Teicoplanin allergy, and these patients will be given another dose in future, not knowing that they are seriously allergic. Serious allergic reactions, also known as anaphylaxis, can be life threatening.

The patients which we recruit to our study will come to us through the perioperative allergy service. They will have had a reaction to a general anaesthetic, but will also have had teicoplanin as part of the anaesthetic.

We are not sure why allergy skin testing, which is fairly reliable for most other drugs, is so unreliable in detecting teicoplanin allergy. We do know that some drugs need to mix with proteins in the blood before they trigger an allergy. We would like to replicate this by mixing the teicoplanin with the patients' own blood and using this for the skin testing, to see if we get a more reliable result compared with the plain drug. Using the patient's own serum to do skin testing is an established test (the 'autologous serum test') used in certain immunological conditions, we are simply going to use it as a vehicle to test our theory.

We will recruit 20 adult patients referred with a recent history of anaphylaxis under anaesthesia, where teicoplanin has been given and is one of the drugs under suspicion of having caused the allergy. In addition to the usual allergy skin testing, which would be done anyway as part of standard allergy investigation, we will perform extra tests using autologous serum for this trial.

We hope to find a better way of testing for Teicoplanin allergy, so that patients are not put at risk where the allergy has been missed because of an unreliable test.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Allergy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Teicoplanin allergy testing Autologous Serum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Teicoplanin allergy testing using autologous serum

20 adult patients with history of anaphylaxis under anaesthesia ( the index episode), where teicoplanin has been given during the index episode will be recruited. In addition to usual skin testing with Teicoplanin directly onto the skin, we will perform skin testing with Teicoplanin- added autologous serum. The trial will be conducted as part of the same routine elective allergy skin-testing appointment for other drugs given during the index episode.

Group Type OTHER

Teicoplanin Allergy Testing using autologous serum

Intervention Type DIAGNOSTIC_TEST

In addition to performing teicoplanin allergy skin testing using standard recommended Teicoplanin concentration, we will perform skin testing using autologous serum, the supernatant which is obtained via centrifugation. Skin testing ( skin prick test and intradermal test) will be performed with these additional samples:

1. STpre: Teicoplanin added to blood sample pre-centrigufation.
2. STpost: Teicoplanin added to supernatant post-centrigufation.
3. ST0: Supernatant with no additives ( serum negative control)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Teicoplanin Allergy Testing using autologous serum

In addition to performing teicoplanin allergy skin testing using standard recommended Teicoplanin concentration, we will perform skin testing using autologous serum, the supernatant which is obtained via centrifugation. Skin testing ( skin prick test and intradermal test) will be performed with these additional samples:

1. STpre: Teicoplanin added to blood sample pre-centrigufation.
2. STpost: Teicoplanin added to supernatant post-centrigufation.
3. ST0: Supernatant with no additives ( serum negative control)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients 18 years old and above who have suffered suspected anaphylaxis under anaesthesia (the 'index episode'), where teicoplanin has been given

Exclusion Criteria

* Patients unable to stop drugs that would interfere with skin tests prior to study- e.g. antihistamines or certain anti-psychotics
* Pregnancy
* Patients under age 18 years
* Patients with elevated baseline mast cell tryptase requiring further investigation
* Patients with blood-borne viruses such as Hep B, C and HIV
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Southampton NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Linda Nel, MB BCh FRCA

Role: STUDY_CHAIR

University Hospital Southampton NHS Foundation Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Southampton

Southampton, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Linda Nel, MB BCh FRCA

Role: CONTACT

Phone: 07957543839

Email: [email protected]

Xi Ying Soo, MBBS

Role: CONTACT

Phone: 023 8077 7222

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Linda Nel, MB BCh, FRCA

Role: primary

Xi Ying Soo, MBBS, MRCP(UK)

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Liccardi G, D'Amato G, Canonica GW, Salzillo A, Piccolo A, Passalacqua G. Systemic reactions from skin testing: literature review. J Investig Allergol Clin Immunol. 2006;16(2):75-8.

Reference Type BACKGROUND
PMID: 16689179 (View on PubMed)

Savic LC, Garcez T, Hopkins PM, Harper NJ, Savic S. Teicoplanin allergy - an emerging problem in the anaesthetic allergy clinic. Br J Anaesth. 2015 Oct;115(4):595-600. doi: 10.1093/bja/aev307.

Reference Type BACKGROUND
PMID: 26385667 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://pubmed.ncbi.nlm.nih.gov/33475206/

Autologous serum skin test reactions in chronic spontaneous urticaria differ from heterologous cell reactions

https://www.bsaci.org/guidelines/bsaci-standard-operating-procedures/

BSACI Standard Operating Procedures- Skin Prick Test

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

345535

Identifier Type: OTHER

Identifier Source: secondary_id

RHM CRI0456

Identifier Type: -

Identifier Source: org_study_id